IL179254A - Anti-theileriosis vaccine - Google Patents
Anti-theileriosis vaccineInfo
- Publication number
- IL179254A IL179254A IL179254A IL17925406A IL179254A IL 179254 A IL179254 A IL 179254A IL 179254 A IL179254 A IL 179254A IL 17925406 A IL17925406 A IL 17925406A IL 179254 A IL179254 A IL 179254A
- Authority
- IL
- Israel
- Prior art keywords
- vaccine
- cells
- growth medium
- per
- dmso
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 48
- 208000001117 Theileriasis Diseases 0.000 title claims description 10
- 210000004027 cell Anatomy 0.000 claims description 54
- 241000283690 Bos taurus Species 0.000 claims description 33
- 244000309466 calf Species 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000001963 growth medium Substances 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000002577 cryoprotective agent Substances 0.000 claims description 12
- 241000238876 Acari Species 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- 210000001563 schizont Anatomy 0.000 claims description 7
- 239000012888 bovine serum Substances 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 230000007918 pathogenicity Effects 0.000 claims description 6
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000006285 cell suspension Substances 0.000 claims description 3
- 238000011109 contamination Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000000670 limiting effect Effects 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 229940056360 penicillin g Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 210000003046 sporozoite Anatomy 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 229940049018 mycostatin Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000405 serological effect Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 241000223777 Theileria Species 0.000 claims 1
- 241000223778 Theileria annulata Species 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000002649 immunization Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 241001586444 Trilophidia annulata Species 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000001524 infective effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 241001494479 Pecora Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229950008349 buparvaquone Drugs 0.000 description 2
- KLLIVCPQDTYMLC-HDJSIYSDSA-N chembl292009 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1CC1=C(O)C(=O)C2=CC=CC=C2C1=O KLLIVCPQDTYMLC-HDJSIYSDSA-N 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- GATQERNJKZPJNX-LDXVYITESA-N 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 GATQERNJKZPJNX-LDXVYITESA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000721156 Chloranthus spicatus Species 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- SCEVFJUWLLRELN-UHFFFAOYSA-N imidocarb Chemical compound C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 SCEVFJUWLLRELN-UHFFFAOYSA-N 0.000 description 1
- 229960004683 imidocarb Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000022676 rumination Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000001064 tick infestation Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A61K39/018—Babesia antigens, e.g. Theileria antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN880DE2004 | 2004-05-14 | ||
| IN2103DE2004 | 2004-10-26 | ||
| PCT/IN2005/000154 WO2005109991A2 (en) | 2004-05-14 | 2005-05-12 | Anti-theileriosis vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL179254A0 IL179254A0 (en) | 2007-03-08 |
| IL179254A true IL179254A (en) | 2011-12-29 |
Family
ID=35394566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL179254A IL179254A (en) | 2004-05-14 | 2006-11-14 | Anti-theileriosis vaccine |
Country Status (5)
| Country | Link |
|---|---|
| AP (1) | AP2709A (ru) |
| IL (1) | IL179254A (ru) |
| MA (1) | MA28656B1 (ru) |
| RU (1) | RU2404800C2 (ru) |
| WO (1) | WO2005109991A2 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023072178A1 (en) * | 2021-10-27 | 2023-05-04 | Porton Advanced Solutions Ltd. | Methods for developing a cell line for producing virus in suspension cell culture |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2914813C2 (de) * | 1979-04-11 | 1984-04-19 | Vsesojuznyj institut eksperimental'noj veterinarii, Moskva | Lebend-Impfstoff gegen Theieriosis beim Rindvieh und Verfahren zu dessen Herstellung |
-
2005
- 2005-05-12 WO PCT/IN2005/000154 patent/WO2005109991A2/en active Application Filing
- 2005-05-12 AP AP2006003856A patent/AP2709A/xx active
- 2005-05-12 RU RU2006144451/15A patent/RU2404800C2/ru not_active IP Right Cessation
-
2006
- 2006-11-14 IL IL179254A patent/IL179254A/en active IP Right Grant
- 2006-12-08 MA MA29521A patent/MA28656B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2709A (en) | 2013-07-30 |
| AP2006003856A0 (en) | 2006-12-31 |
| RU2006144451A (ru) | 2008-06-20 |
| WO2005109991A2 (en) | 2005-11-24 |
| WO2005109991A8 (en) | 2006-08-24 |
| MA28656B1 (fr) | 2007-06-01 |
| RU2404800C2 (ru) | 2010-11-27 |
| WO2005109991A3 (en) | 2006-03-30 |
| IL179254A0 (en) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pipano | Schizonts and tick stages in immunization against Theileria annulata infection | |
| US7462359B2 (en) | Neospora vaccines | |
| CN109568573A (zh) | 疫苗组合物及其制备方法和应用 | |
| NO159782B (no) | Anordning ved fjaersystem, foerst og fremst paa kjoeretoeyer. | |
| Fish et al. | Vaccination of cattle against B. bovis infection with live attenuated parasites and non-viable immunogens | |
| Yunker et al. | Attenuation of Babesia bovis by in vitro cultivation | |
| RU2403063C1 (ru) | Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота | |
| IE46498B1 (en) | New vaccine | |
| EP0100710B1 (en) | Vaccine for the immunization of animals and men against toxoplasma gondii | |
| IL179254A (en) | Anti-theileriosis vaccine | |
| Yoshida et al. | Establishment of an attenuated ML-17 strain of Japanese encephalitis virus. | |
| Lawson et al. | Safety and immunogenicity of ERA strain of rabies virus propagated in a BHK-21 cell line. | |
| US3479430A (en) | Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same | |
| Hsu et al. | The effect of vaccination with a live attenuated strain of Japanese encephalitis virus on stillbirths in swine in Taiwan | |
| US3585108A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| KR101210082B1 (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| IQBAL et al. | Immune response of rabbits to hemorrhagic septicemia vaccine formulations adjuvanted with montanide ISA-206, paraffin oil and alum | |
| EP0687471A1 (en) | Production of an efficacious toxoplasma gondii bradyzoite vaccine in tissue culture | |
| US3704203A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| JP3043353B2 (ja) | ワクチン | |
| Pipano | Vaccination of cattle against Theileria annulata using culture-derived schizonts | |
| Pipana | Virulence and immunogenicity of cultured Theileria annulata schizonts | |
| RU2395297C1 (ru) | Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи и лептоспироза крупного рогатого скота | |
| KR20120039113A (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| Alvarez-Martinez et al. | Development of a live attenuated vaccine for the control of bovine babesiosis in Mexico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |